Can IVF-inspired skincare move AVL beyond beauty marketing into longevity science?
Beauty wants biotech credibility. AVL’s IVF-inspired skincare push tests whether longevity science can reshape premium skincare.
Pharma & Biotech
Medical Devices & Diagnostics
Mevion’s European expansion gains momentum with Southern Italy proton therapy project
Proton therapy is precise but hard to scale. Mevion’s Naples win tests whether compact systems can shift access across Southern Europe.
Pharma & Biotech
Can Ferring turn real-world ADSTILADRIN use into a broader NMIBC treatment strategy?
Bladder-sparing therapy needs better sequencing. Ferring’s ADSTILADRIN re-induction signal raises hope, but durability is the real test.
Pharma & Biotech
Is PMS relief becoming a consumer wellness category? Bayer’s Midol in Motion campaign suggests so
PMS relief is moving beyond pain pills. Bayer’s Midol campaign ties symptom care to movement, creators, and menstrual wellness.
Pharma & Biotech
Can Amylyx turn open-label AMX0035 signals into a credible Phase 3 Wolfram syndrome trial?
Amylyx has rare disease momentum, but open-label data are not destiny. AMX0035 now faces its real Wolfram syndrome test.
Medical Devices & Diagnostics
What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Medical Devices & Diagnostics
Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care
Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.
Pharma & Biotech
Can Agenus turn botensilimab and balstilimab into a serious post-ICI liver cancer contender?
Post-ICI liver cancer has few strong options. Agenus’ BOT plus BAL data raise the next question: can durability survive larger trials?
Pharma & Biotech
NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals
Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.
Medical Devices & Diagnostics
Why Novanta’s June healthcare conference appearance matters after its Q1 revenue rebound
Medtech suppliers are under pressure to prove growth quality. Novanta’s Jefferies appearance may sharpen the investor debate.